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Type 2 diabetes (T2D) is a common, polygenic chronic disease with high heritability. The purpose of this whole-genome
association study was to discover novel T2D-associated genes. We genotyped 500 familial cases and 497 controls with
1300,000HapMap-derived tagging single-nucleotide–polymorphism (SNP)markers.When a stringent statistical correction
for multiple testing was used, the only signiﬁcant SNP was at TCF7L2, which has already been discovered and conﬁrmed
as a T2D-susceptibility gene. For a replication study, we selected 10 SNPs in six chromosomal regions with the strongest
association (singly or as part of a haplotype) for retesting in an independent case-control set including 2,573 T2D cases
and 2,776 controls. The most signiﬁcant replicated result was found at the AHI1-LOC441171 gene region.
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Type 2 diabetes (T2D [MIM 222100]) is considered a ma-
jor medical burden on society.1 Given the high heritabil-
ity and public health importance of the trait, the identi-
ﬁcation of the underlying genes has been a high-priority
mission of the scientiﬁc community for many years.2,3
Nevertheless, only a handful of genes contributing to the
predisposition of T2D have been conﬁrmed, including
TCF7L2 (MIM 602228), PPARg (MIM 601487), KCNJ11
(MIM 600937), and CAPN10 (MIM 605286).4–9 These
genes, however, account for only a small fraction of the
genetic variation of the disease. Although conventional
linkage-based studies in affected families have had some
success in providing consistent data on linkage peaks in
T2D,3,10–13 it is now believed that linkage analysis may lack
the statistical power and mapping resolution to identify
genes affecting common complex traits such as T2D.14 As-
sociation studies are the alternative approach and are cur-
rently considered the method of choice for the identiﬁ-
cation of genes affecting common complex traits.11 Until
recently, association studies have been limited to speciﬁc
genes or chromosomal regions. As a result of the Human
Genome Project, the SNP Consortium, and the HapMap
Project, there is today a wealth of knowledge regarding
human SNPs and the way they can be used for whole-
genome association (WGA) studies. Furthermore,microar-
ray technologies now allow genotyping of the genome at
the necessary density.
A French Canadian consortium9 recently presented
the results of the ﬁrst WGA study of T2D, indicating sev-
eral novel T2D candidate genes. Our study, performed
with the same technology, allows a comparison of two
independent WGA studies. The genotyping platform used
(HumanHap300 [Illumina]) contains 317,000 SNPs,which
were selected on the basis of the HapMap data.
Material and Methods
Subjects
The population studied includes 500 cases and 497 controls from
four different populations, all white. Speciﬁcally, we studied 201
cases and 200 controls from eastern Finland (EF), 200 cases and
197 controls of Ashkenazi Jewish (AJ) origin from Israel, and 99
cases and 100 controls from Germany (GE) and England (UK).
The Germans were from the region of Pomerania in northeastern
Germany, and the English were from the Manchester region. Two
of the populations represent genetically homogenous founder
populations (EF and AJ), whereas the Germans and English rep-
resent the general European population. Cases and controls were
sex matched so that the proportion of each sex was identical in
the cases and controls within each population. The controls were
selected to be older than the cases, to reduce the chance that
some of the controls will develop the disease in the future. Similar
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study protocols and case report forms were used at all sites and
were correspondingly accepted by their ethics committees. In-
formed consent forms were signed by all subjects participating
in this study.
T2D Inclusion/Exclusion Criteria
Subjects meeting the following three criteria were deﬁned as pa-
tients with T2D: (1) either having regular treatment with an oral
hypoglycemic agent (463 of 500 cases used antidiabetic medi-
cation) or having treatment only with diet while also having
either an HbA1c level 7.5% or a fasting blood glucose level at
least 6.7 mmol/liter, (2) with disease manifestation at age 60 years
or earlier, and (3) with family history of T2D (at least one parent
or sibling). Patients given diagnoses of non-T2D were excluded.
Control Inclusion/Exclusion Criteria
Subjects meeting the following two criteria were deﬁned as con-
trols for all populations except AJ blood donors: (1) receiving
neither insulin treatment nor oral antidiabetic medication and
having glucose levels !5.5 mmol/liter and (2) having no family
history of diabetes (not in grandparents, parents, siblings, or off-
spring). Some AJ control samples were obtained from blood do-
nors (see below) who declared not having any chronic disease.
Since it is a major risk factor and etiology of T2D, obesity was
not a selection criterion for either the cases or the controls. Con-
sequently, the mean BMI was considerably higher among the
cases than the controls.
WGA Sample-Collection Process
Eastern Finland.—The data and sample collection was performed
in two places—by the Research Institute of Public Health, Uni-
versity of Kuopio (166 cases and 166 controls), and by Oy Food-
ﬁles (35 cases and 34 controls), Kuopio, Finland. In the university
collection, the sampling frame was the 17,100 examinees of a
questionnaire survey mailed in 2003 to all households in a small
region within the founder population, for the “North Savo Pro-
ject.” In this survey, information about medical and family his-
tory and medical treatments and consent forms for further par-
ticipation were collected. The subjects were reexamined in 2004
and 2005 at the institute, and blood samples were collected for
DNA extraction and other measurements, in accordance with the
protocol. The Foodﬁles collection was performed between late
2005 and early 2006 with the use of newspaper advertisements
in the surrounding communities of the city of Kuopio, with use
of inclusion criteria identical to that of the university collection.
On average (including both of these collections), 3.1 of the 4
grandparents were of eastern Finnish origin. A total of 201 T2D
cases (99 women and 102 men) and 200 matched nondiabetic
controls (99 women and 101 men) were included in the study.
Ashkenazi Jews.—Subjects included in the study were collected
in Israel by the patients’ physicians in specialized clinics. We
included 200 subjects with T2D (82 men and 118 women, mean
age 64 years), each with 3 ormore blood relatives of seconddegree
or closer who had T2D. Two hundred matching nondiabetic con-
trol samples (82 men and 118 women, mean age 74 years) were
collected from the Israeli Blood Bank and from elderly patients
visiting general practitioners’ clinics. All subjects were of AJ
origin.
Germany.—Cases were sampled from ∼800 inpatients with T2D
from the Clinic for Diabetes and Metabolic Diseases Karlsburg
and from theDepartment of InternalMedicine of the ErnstMoritz
Arndt University Greifswald who were examined by a study phy-
sician andwho fulﬁlled the inclusion criteria. Correspondingcon-
trols (matched by sex and age) were selected from among the
3,900 nondiabetic examinees of the population-based “Study of
Health in Pomerania 1997–2001” cohort.15 Data on familyhistory
of diabetes, medication use, and comorbidity were gathered by a
standardized face-to-face interview and measurement of blood
pressure and BMI, and laboratory analyses were performed using
standardized procedures. For the patients with T2D, additional
information was drawn from the patient records. A total of 49
cases (24 women and 25 men) and 50 matched healthy controls
(24 women and 26 men) from Germany were included in the
study.
England.—A total of 50 cases (31 women and 19 men) and 50
matched nondiabetic controls (31 women and 19 men) were in-
cluded in the study. The cases were selected from among 8,300
registered patients with T2D in the city of Salford whose baseline
characteristics matched those of the catchment population with
T2D ( ) on the basis of age, sex, and durationnp 8,300/220,000
of diabetes. Family history data was gathered via a telephone
survey with the use of a standardized questionnaire that included
questions about the patients and their parents, children, siblings,
and grandparents. The controls were selected from among the
examinees of the Age and Cognitive Performance Research Cen-
tres volunteer panel, a group of 16,000 older adults who have
been described in detail elsewhere.16 A cohort of ∼2,000 of these
individuals have DNA archived in the Dyne-Steel DNA bank, and
456 of these volunteers, residents of Greater Manchester, had
taken part in a research study in 2001 that included medical
history, including that of T2D, and measurement of HbA1c. Of
these, subjects were identiﬁed to sex match diabetic cases from
Manchester.
DNA Samples
At each participating site, DNA was extracted from whole blood
with the use of standard methods. The quantity and purity of
each DNA sample was uniformly determined by absorbance
measurements with a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies). A sample was qualiﬁed for WGA anal-
ysis if the A260:A280 ratio was 1.7 and the DNA concentra-
tion was 160 ng/ml. Before WGA analysis, the samples were di-
luted to a concentration of 60 ng/ml in reduced Tris EDTA buffer
(TEKnova).
Genotyping Platforms and SNPs
The whole-genome genotyping of DNA samples was performed
using Sentrix HumanHap300 BeadChips and Inﬁnium II geno-
typing assays (Illumina). The HumanHap300 BeadChip contained
317,503 tag SNPs derived from the International HapMap Project.
The genotyping reactions were performed according to the Single-
Sample BeadChip Manual process described in detail in the In-
ﬁnium II Assay System Manual (Illumina). In brief, 750 ng of
genomic DNA was subjected to whole-genome ampliﬁcation at
37C for 20–24 h. Products were fragmented, precipitated, and
resuspended in hybridization buffer. The resuspended samples
were denatured at 95C for 20 min, were loaded to BeadChips,
and were placed in a hybridization chamber for 16–20 h at 48C.
After hybridization, themis- and nonhybridizedDNAwaswashed
away from the BeadChips, and an allele-speciﬁc single-base ex-
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Figure 1. Distribution of MAFs in 317,503 SNPs
Figure 2. Vertical lines plotted for each SNP analyzed, placed
according to their chromosomal locations. The height of the lines
correspond to the nominal P value (plotted as logP) of each SNP
as obtained from a single-point analysis with use of a Cochran-
Mantel-Haenszel x2 test (see the “Material and Methods” section).
The horizontal dashed lines (at , )7 logPp 6.64 Pp 2.3# 10
correspond to the statistical threshold adjusted for multiple test-
ing and an overall statistical signiﬁcance of .05, after 1,000
permutations.
tension of the oligonucleotides on the BeadChip was performed
in a 48-position Slide Chamber Rack (GenePaint [Tecan]), with
the use of labeled deoxynucleotides and the captured DNA as a
template. After staining of the extended DNA, BeadChips were
washed and scanned with the BeadArray Reader (Illumina), and
genotypes from samples were called using the BeadStudio 2.0
software (Illumina).
The Centaurus genotyping methodology uses standard PCR
that uses primers to produce an amplicon of fewer than a few
hundred residues. Allele-speciﬁc probes displaying a ﬂuorescent
dye at the 3′ end, a quencher at the 5′ end, and a short enhancer
oligonucleotide (∼8–15 residues in length) are hybridized to the
amplicon.17 The enhancer oligonucleotide hybridizes to the am-
plicon 3′ relative to the allele-speciﬁc probes. The uniqueness of
the assay is derived through a design that produces a single-base
gap between the two probes and the enhancer oligonucleotide.
This gap creates a synthetic abasic site, which directs the speci-
ﬁcity of the enzyme endonuclease IV to this speciﬁc location.
This enzyme will cleave the dye on the fully complementary
probe, thus separating the dye from the quencher molecule and
producing a ﬂuorescent signal. The probe that has a mismatch
to the target remains uncleaved.
Initial SNP Selection for Statistical Analysis
To check that the same individual was not included twice in the
study, a set of 23 SNPs (one polymorphic SNP from each chro-
mosome) was compared across all subjects before the statistical
analysis. SNP quality was also assessed on the basis of three cri-
teria: the call rate (CR), minor-allele frequency (MAF), andHardy-
Weinberg (H-W) equilibrium. The CR is the proportion of samples
genotyped successfully, regardless of whether the genotypes are
correct. The MAF is the frequency of the allele that is less frequent
in the study sample. H-W equilibriumwas tested for controlswith
use of the standard x2 test of goodness of ﬁt with 1 df. A SNP not
in H-W equilibrium can be due to genotyping error or to some
unknown population dynamics (e.g., random drift or selection).
Only the SNPs that had CR 190% and MAF 11% and were in H-
W equilibrium (x2 test statistic !27.5 in controls) were used in
the statistical analysis. A total of 315,917 of 317,503 SNPs avail-
able in the Illumina HumanHap300 assay fulﬁlled the above cri-
teria and were included in the statistical analysis.
Single-Point Analysis
The single-point analysis was performed using Cochran-Mantel-
Haenszel x2 tests to detect association between disease status and
the allele frequency of each SNP, with stratiﬁcation of the samples
by population. Our sample set consists of four different popu-
lations. Cases and controls were carefully matched within each
population by sex and ethnicity, to avoid spurious associations.
Accounting for multiple testing, we computed the signiﬁcance
threshold, using 10,000 permutations. It should be noted that
the number of permuted P values is SNPs and10,000# 315,917
is thus appropriate for obtaining a very accurate threshold. The
disease status was randomly reassigned to subjects within each
population, and the same protocol of testing was applied to the
permuted samples. The statistical analysis was performed using
the R programming environment. We used the speciﬁcations of
the function “mantelhaen.test” in the implementation of the
test.
In addition, the associations of genotypes with T2D were an-
alyzed with an adjustment for age, sex, and population by use of
binary logistic modeling. The population was entered as a cate-
gorical variable, so each population had its own correction for
the dependent variable.
Haplotype Analysis
Haplotypes of large chromosomal segments (e.g., 400 SNPs) were
estimated ﬁrst with the HaploRec program, and then the seg-
ments were joined to create fully phased chromosomes.18 The
HaploRec program was used because it has recently been found
to be extremely efﬁcient and powerful compared with popular
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Table 1. SNPs with the Strongest Association with T2D in the WGA Study
SNP Markera P Allelic ORb (95% CI)
Minor
Allele Chromosome Gene
rs7903146 5.52#108 1.71 (1.41–2.08) A 10 TCF7L2
rs7901695 3.42#107 1.66 (1.37–2.01) G 10 TCF7L2
rs12255372 5.31#107 1.64 (1.35–2.00) A 10 TCF7L2
rs6712932 6.25#106 .66 (.55–.79) G 2 None
rs7910485 1.02#105 1.58 (1.29–1.94) A 10 STK32C
rs200801 1.78#105 1.48 (1.24–1.77) A 21 None
rs1535435 1.86#105 2.34 (1.58–3.46) A 6 AHI1
rs158081 2.36#105 .66 (.54–.80) G 21 None
rs9494266 2.67#105 2.31 (1.56–3.42) A 6 LOC441171
rs2254434 3.86#105 .68 (.56–.81) A 21 None
a Markers selected for the replication study are highlighted in bold.
b ORs presented are for all four populations pooled.
Table 2. Haplotypes with the Strongest Association with T2D in the WGA
Haplotype SNP Markersa P Haplotype ORb (95% CI) Haplotype Chromosome Gene
1 rs7895307, rs7901695, and rs7903146 3.47#108 1.76 (1.44–2.16) GGA 10 TCF7L2
2 rs3936203, rs10933514, and rs4630763 5.02#107 1.77 (1.41–2.21) GGC 2 None
3 rs2824577 and rs200801 1.28#106 .64 (.54–.77) AG 21 None
4 rs2288440, rs31299, rs40979, rs173738, and rs1445946 1.30#106 1.61 (1.33–1.96) AACGG 5 MYO10
5 rs1749718, rs1742083, and rs8018904 3.02#106 .64 (.53–.77) GAC 14 TTC7B
6 rs10491118, rs854685, and rs854692 3.97#106 .34 (.21–.55) CAA 17 CCL14-CCL15
7 rs4495839, rs4466762, rs11596854, rs4128664, and rs925587 4.13#106 .46 (.33–.64) AAGAG 10 ANTXRL
8 rs1042778, rs237887, rs2268490, rs2268491, and rs237889 5.82#106 .04 (.01–.31) AGAAG 3 OXTR
9 rs930306, rs13136503, rs7682282, rs13106255, and rs7695711 5.86#106 .28 (.16–.50) AGAGG 4 None
10 rs6712932 and rs1545122 6.86#106 .66 (.54–.79) GG 2 None
a Markers selected for the replication study are highlighted in bold.
b OR for the deﬁned haplotype versus all other haplotypes (per increment of the number of copies). Haplotypes 1, 4, 5, 6, and 8 are intragenic.
alternatives.19 Each population was haplotyped separately be-
cause population haplotype frequencies differ; thus, estimation
of haplotypes within a population is more accurate than use of
the pooled data. Populations were combined, and haplotype fre-
quencies were estimated with the HPM program.20 The program
was used to test haplotypes of length 2, 3, 4, and 5 SNPs. For
each haplotype, HPM calculates how many times the haplotype
is present in case and control chromosomes and howmany times
it is not present in case and control chromosomes. This results
in a 2#2 table for each single haplotype tested against all other
haplotypes. To assess statistical signiﬁcance, 10,000 permutations
were performed similar to the single-point analysis.
Replication Study
The replication study included 2,573 T2D cases and 2,776 nor-
moglycemic control subjects given diagnoses in accordance with
the 1997 American Diabetes Association criteria. The T2D cases
were recruited at the Sud Francilien Hospital or at the Centre
National de la Recherche Scientiﬁque UMR8090, Lille. All cases
had family history of T2D (i.e., the proband had at least one ﬁrst-
degree relative with T2D). Individuals with maturity-onset dia-
betes of the young or neonatal or mitochondrial diabetes were
excluded. The control subjects were obtained from a prospective
population-based cohort of middle-aged subjects ( atNp 5,153
baseline).21 They had fasting blood glucose level !6.1 mmol/liter
at baseline and during a 9-year follow-up (measurements at 0, 3,
6, and 9 years), and their family histories were free of T2D. Ge-
notyping of the 10 SNPs in these samples was performed with
the TaqMan technology (Applied Biosystems).
Results
In the initial WGA study, we genotyped 500 cases and 497
controls, producing 1300 million genotype results. The
cases and controls were selected from four populations
(EF, AJ, GE, and UK). All populations are of white origin
but are distinct, thus allowing the examination of the
common basis of any ﬁnding across different populations.
Sex was matched between cases and controls within each
population. The age distribution was higher in controls,
to include as few as possible nondiabetic individuals who
may develop the disease in the future.
The average CR for all SNPs was very impressive (99.5%),
with only 1,341 (0.42%) of the 317,503 SNPs tested hav-
ing a CR !90%. Four subjects chosen randomly were ge-
notyped twice for all SNPs. Reproducibility of genotypes
was 199.9%. In addition, to study the validity of the In-
ﬁnium method, 12 HumanHap300 SNPs were also geno-
typed for 393 samples with the Centaurus methodology.17
The concordance of the genotypes was 199.9%. Figure 1
presents the distribution of the MAF of all SNPs. As ex-
pected, the MAF was found to be quite uniformly distrib-
uted between 0.1 and 0.5. Of the 317,503 SNPs available
in the Illumina HumanHap300 assay, 315,917 fulﬁlled our
criteria of having CR 190% and MAF 11% and not being
in extreme H-W disequilibrium ( ) and were7P 1 1.5# 10
included in the statistical analysis.
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Table 3. Detailed Results of the 10 SNPs Selected for Replication
SNP Gene
Minor
Allele
EFa AJb GE and UKc
Four Populations
Combinedd
MAF OR P MAF OR P MAF OR P MAF OR P
rs6712932 None G .294 .568 .0003 .448 .702 .0135 .317 .699 .0977 .360 .657 .000008
rs7910485 STK32C A .287 1.750 .0004 .246 1.457 .0232 .236 1.500 .0876 .260 1.583 .000008
rs200801 None A .365 1.479 .0078 .504 .661 .0036 .399 1.454 .0685 .427 1.481 .000016
rs1535435 AHI1 A .039 3.565 .0019 .065 1.626 .0959 .101 2.948 .0024 .062 2.337 .00001
rs9494266 LOC441171 A .039 3.565 .0019 .065 1.626 .0959 .098 2.830 .0037 .061 2.307 .00002
rs253336 MYO10 A .288 1.221 .2003 .198 1.668 .0046 .317 1.545 .0446 .258 1.419 .00067
rs173738 MYO10 A .307 .697 .0191 .402 .719 .0230 .359 .732 .1357 .355 .716 .00037
rs31313 MYO10 A .268 1.595 .0037 .181 1.668 .0063 .178 .903 .6989 .215 1.46 .00057
rs942740 TTC7B A .187 1.691 .0042 .194 1.271 .1830 .121 2.217 .0124 .177 1.55 .00022
rs1749718 TTC7B A .459 1.513 .0036 .364 1.228 .1652 .490 1.497 .0451 .427 1.386 .00032
a 201 cases and 200 controls.
b 200 cases and 197 controls.
c 99 cases and 100 controls.
d 500 cases and 497 controls.
Table 4. Association Results of the Replication Study in 2,573 T2D
Cases and 2,776 Controls
SNP Gene
Minor
Allele MAF ORa (95% CI) P
rs6712932 None G .351 1.117 (1.030–1.212) .008
rs7910485 STK32C A .247 .980 (.896–1.072) .657
rs200801 None A .477 1.031 (.955–1.113) .433
rs1535435 AHI1 A .096 1.287 (1.126–1.470) .0002
rs9494266 LOC441171 A .100 1.308 (1.149–1.489) .00005
rs253336 MYO10 A .300 .986 (.906–1.073) .746
rs173738 MYO10 A .357 1.060 (.976–1.151) .167
rs31313 MYO10 A .193 1.024 (.928–1.130) .634
rs942740 TTC7B A .185 .858 (.777–.948) .003
rs1749718 TTC7B A .499 .878 (.812–.950) .001
a ORs are presented for the minor allele versus the major allele.
Because we analyzed four different populations under
the same null hypothesis and model, the statistical infer-
ences for single SNPs were based on the Cochrane-Mantel-
Haenszel statistic. Figure 2 presents the nominal P value
of each of the SNPs tested across the entire genome. Ex-
cept for one SNP on chromosome 10 at the TCF7L2 gene
(rs7903146), no other SNP crossed the stringent corrected-
statistical-signiﬁcance threshold (ﬁg. 2, dashed lines at
, , based on 10,000 permu-7 log (P)p 6.60 Pp 2.5# 10
tations). Table 1 presents the detailed results for the 10
most signiﬁcant SNPs with MAF 10.05. The effect of sta-
tistical adjustment for age, sex, and population was small
(data not shown).
The intragenic SNPs with the next strongest univariate
association were in STK32C, AHI1 (Abelson helper inte-
gration site 1 [MIM 608894]), and LOC441171, which
ﬂanks and overlaps AHI1. As shown in ﬁgure 2, the AHI1
and LOC441171 markers were in complete linkage dis-
equilibrium (LD) ( ). Since haplotype analysis may′D p 1
have higher statistical power, the data were also analyzed
using haplotypes for all possible sets of two to ﬁve con-
secutive SNPs (table 2). The next strongest haplotypes,
after those in TCF7L2, were in the genes MYO10 (MIM
601481) and TTC7B. With use of a stringent correction
for multiple testing, only a P value of 2.02#108 (based
on 10,000 permutations) can be considered signiﬁcant in
its own right; no haplotype crossed this value.
Ten SNPs (table 3)—including the most promising ones
from tables 1 and 2, two additional SNPs in MYO10
(rs31313 and rs253336), and one additional SNP in TTC7B
(rs942740)—were retested in a case-control set that was
independent of the WGA subjects: 2,573 cases and 2,776
controls from France. These cases and controls have al-
ready been found to be well matched and appropriate for
association studies of T2D.9 SNPs in TCF7L2 were not in-
cluded in the replication study, since this gene has been
well established as a T2D-susceptibility gene, including in
the samples used here for the replication study.9 Table 3
presents the detailed results of these 10 SNPs in the initial
WGA samples, and table 4 presents the results of these
SNPs in the replication samples. Five of these 10 SNPs
reached a nominal statistical signiﬁcance of . How-P ! .01
ever, only two SNPs (rs1535435 and rs9494266) in the
same haplotype reached the Bonferroni-corrected P value
!.005 for allelic association in the replication study (Pp
and , respectively) and exhibited odds.0002 Pp .00005
ratios (ORs) in the same direction as those found in the
initial WGA study. (SNPs in the TTC7B gene also reached
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Figure 3. Pairwise LD diagram for SNPs in the AHI1 gene region. The LD between pairs of SNPs is presented using D′, which was
calculated from the DiaGen genotyping data with Haploview software. The bar graph indicates the negative logarithm of the P value
for each SNP from single-point analysis.
a P value !.005; however, ORs were in opposite directions.)
The respective P values for rs1535435 and rs9494266 in a
pooled Cochran-Mantel-Haenszel analysis of the WGA to-
gether with the replication study were 106 and 2.28#
107. Figure 3 presents the haplotype structure around
the signiﬁcant region. The most signiﬁcant ﬁnding was
on chromosome 6, located within an LD block of 178 kb
encompassing 19 introns of the AHI1 gene and the non–
protein-coding LOC441171 on chromosome 6 (ﬁg. 3). This
region has been identiﬁed elsewhere as a T2D-suscepti-
bility locus in several linkage studies.22,23 LOC441171 (or
C6orf217) is a primate-speciﬁc gene expressed in brain,
pancreas, and liver, and it does not seem to encode a func-
tional protein. Therefore, AHI1 might be a preferred can-
didate gene, although a functional effect of LOC441171
cannot be entirely discarded.
AHI1 encodes a unique AHI1 (Jouberin) protein, the
only known protein containing an SH3 motif, seven
WD40-repeat domains, and multiple SH3-binding do-
mains (PXXP motifs).24,25 WD motifs are evolutionarily
conserved across the species and form a stable b-propeller
structure that serves as a platform for protein-protein in-
teractions.26 Speciﬁc functions of WD-repeat proteins
seem to be determined by other motifs and domains rep-
resented in the protein.26 Therefore, the domain structure
suggests that AHI1 is likely to act as a scaffold protein and
to participate in a variety of processes such as signal trans-
duction, cytoskeleton organization, cell cycle, and cell-cell
communication.26,27 However, the exact function of AHI1
is not clariﬁed yet, and additional studies will be required
to determine its possible involvement in T2D.
The SNPs rs1535435 and rs9494266 may directly affect
susceptibility to T2D or may predispose an individual to
obesity (MIM 601665) and thus indirectly affect suscep-
tibility to T2D. For 1,084 of the cases in the replication
set and 1,084 of the controls, we have BMI information.
In this restricted set, the allelic P values of rs1535435 and
rs9494266 were .005 and .003, respectively. Analyzing
these SNPs with BMI as a covariate resulted in allelic P
values of .019 and .011, respectively. Therefore, although
the observed effect on T2D may be partially mediated
through obesity, it seems that a direct and independent
effect is also present.
Discussion
In the current study, we aimed to assess the potential value
of WGA studies on the basis of HapMap-derived high-
density SNP arrays. To increase statistical power, we pri-
marily used samples from homogeneous founder popu-
lations (801 of the 997 subjects included in this study).
In addition, we included disease cases that have a high
familial prevalence of the disease—on average, more than
two affected relatives in addition to the proband. In spite
of our effort to carefully select samples in a manner that
may increase statistical power and the use of the most
advanced technology available today, a sample of ∼500
cases and ∼500 controls was powerful enough to identify
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only one known gene and to provide suggestive evidence
of the identiﬁcation of other genes affecting T2D. This is
similar to the ﬁndings of another WGA study of T2D.9
Following a genomewide statistical correction, Sladek et
al.9 also found only the TCF7L2 gene to be associated
with T2D. They also performed a replication study in
which eight additional SNPs were replicated.9 Of these
eight SNPs, ﬁve are present in the HumanHap300 mi-
croarray that we used. Interestingly, none of these ﬁve
SNPs reached a nominal statistical signiﬁcance of .01 in
our WGA study. It should be noted that the samples used
for replication by Sladek et al.9 are the same ones used for
replication in the current study.
In the current study, we selected the 10 most promising
SNPs and genotyped them in the replication sample set.
The most promising result was found at the AHI1 gene
region. The selection of only 10 SNPs is somewhat arbi-
trary, and there might be value in testing a signiﬁcantly
larger number of SNPs. The partial inconsistency of the
WGA ﬁndings between populations and studies deserves
further research, since it may suggest either population
speciﬁcity of some of the observed associations, insufﬁ-
cient statistical power, or possible false-positive results in
either study. Population speciﬁcity could be due to dif-
ferences in LD blocks, population-speciﬁc interactions be-
tween genes and nongenetic factors, population-speciﬁc
epigenetic effects, or the different inclusion criteria used
(speciﬁcally, BMI !30 for the cases in the study by Sladek
et al.,9 whereas BMI was not a selection criterion in our
study). The possibility of false-positive results should be
carefully considered, particularly in light of the unex-
pectedly high proportion of SNPs in the replication study
that exhibit a signiﬁcant effect (5 of 10), 3 of them with
ORs in a direction opposite to the initial ﬁndings. Popu-
lation stratiﬁcation is unlikely to be a source of false-pos-
itive results in the initial WGA study, since samples were
carefully matched by ethnicity and sex.More importantly,
the only signiﬁcant result in the initial WGA study was
found in a gene known to affect T2D, providing strong
evidence of the lack of population stratiﬁcation in these
samples. Nevertheless, population stratiﬁcation as a source
of false-positive results in the replication set cannot be
entirely discarded. As in any association study of this kind,
further replication is necessary. On the positive side, the
replication of the TCF7L2 ﬁnding provides strong evi-
dence of the robustness of the WGA-study approach, at
least for the identiﬁcation of genes with allelic ORs 11.7.
Our study also indicates, as has been suggested on a the-
oretical basis,28 that larger sample sizes will be necessary
to unequivocally establish the involvement of genes with
modest ORs (i.e., !1.7) across different populations.
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